Genomenon Inc., an Ann Arbor, Michigan-based artificial intelligence (AI)-driven genomics company, completed a $20 million Series B financing round led by Farmington Hills-based Beringea U.S.
The funds will be used to expand the company’s commercial operations and the development of its genomic data hub, which serves genetic testing labs, hospitals, pharmaceutical, and biopharma companies.
Company: Genomenon Inc.
Round: Series B
Funding Month: March 2022
Lead Investors: Farmington Hills
Company Website: https://www.genomenon.com/
Software Category: AI-driven genomics
About the Company: Genomenon is an AI-driven genomics company whose mission is to save and improve lives by making genomic information actionable for patients with rare genetic diseases and cancer. Keeping pace with the ever-evolving body of knowledge within genomics, Genomenon connects current research with patient DNA to accelerate clinical decision-making and pharmaceutical drug discovery. Genomenon leverages AI to organize the world’s genomic knowledge and put it at the fingertips of doctors and clinicians to diagnose patients with a rare genetic disease and cancer. It also assists researchers with creating precision medicine targeted at molecular drivers of disease.